Back to News
Market Impact: 0.25

Guru Fundamental Report for TMO

TMONDAQ
Company FundamentalsAnalyst InsightsHealthcare & Biotech
Guru Fundamental Report for TMO

Validea's guru fundamental report indicates that Thermo Fisher Scientific (TMO) is a strong candidate based on Partha Mohanram's P/B Growth Investor model, receiving a rating of 66%. The model, which favors low book-to-market stocks with sustained growth characteristics, shows TMO passing key tests related to book/market ratio, return on assets, and cash flow, but failing in areas of advertising, capital expenditures and research and development relative to assets.

Analysis

Thermo Fisher Scientific Inc. (TMO) has been evaluated by Validea's P/B Growth Investor model, based on Partha Mohanram's published strategy, achieving a rating of 66%. This score indicates a moderate alignment with the model's criteria for low book-to-market stocks exhibiting characteristics of sustained future growth, though it remains below the 80% threshold that typically signifies strong interest. TMO successfully meets several fundamental tests, including book/market ratio, return on assets, cash flow from operations to assets, the relationship between cash flow and return on assets, return on assets variance, and sales variance, pointing to current financial robustness and operational efficiency. Conversely, TMO fails the model's tests for advertising to assets, capital expenditures to assets, and research and development to assets. These failures could signal potential underinvestment in key areas typically associated with driving future growth. The associated signals indicate a mixed general sentiment (0.15 score) and a low market impact score (0.25) for this specific report, with TMO's per-ticker sentiment being mildly positive at 0.3.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

mixed

Sentiment Score

0.15

Ticker Sentiment

NDAQ0.00
TMO0.30

Key Decisions for Investors

  • Investors should note Thermo Fisher Scientific's positive current financial health metrics, particularly its return on assets and strong cash flow generation, as identified by the P/B Growth Investor model.
  • Further scrutiny is advisable concerning TMO's long-term growth prospects, specifically investigating its strategies for advertising, capital expenditure, and R&D, given the model's 'fail' ratings in these asset-relative metrics.
  • Given the moderate 66% score from this specific Validea model, which is below the strong interest threshold, investors should consider this analysis as one component of a broader due diligence process rather than a standalone buy signal.